If you've had allergic reactions to GLP-1 receptor agonists, it's crucial to consult your provider before starting tirzepatide treatment
Methylfolate isn't risk-free for everyone
Tirzepatide is currently in Phase III development for adults with obesity or overweight who have weight-related comorbidity, and the FDA is also reviewing it as a treatment for adults with type 2 diabetes
The patent was invalidated the next year, but Novo appealed the decision, and the patent office has yet to make a final determination
The secondary endpoints showed an 18% reduction in the risk of major cardiovascular events and a 20% reduction in the risk of all-cause mortality, according to the European Renal Association announcement
Goal: Support chronic weight management through GLP1 receptor activation, leading to reduced appetite and improved metabolic parameters [1]